0 XP   0   0   0

Atara Biotherapeutics Inc
Buy, Hold or Sell?

Let's analyse Atara Biotherapeutics Inc together

PenkeI guess you are interested in Atara Biotherapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Atara Biotherapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Atara Biotherapeutics Inc

I send you an email if I find something interesting about Atara Biotherapeutics Inc.

Quick analysis of Atara Biotherapeutics Inc (30 sec.)










1. Valuation of Atara Biotherapeutics Inc (5 min.)




Live pricePrice per share (EOD)

$1.88

2. Growth of Atara Biotherapeutics Inc (5 min.)




Is Atara Biotherapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$126.6m$330m-$131.1m-66.0%

How much money is Atara Biotherapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$57m-$85m$27.9m?
Net Profit Margin-9,199.0%-1,796.0%--

How much money comes from the company's main activities?

3. Financial Health of Atara Biotherapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#381 / 1215

Most Revenue
#246 / 1215

Most Profit
#1090 / 1215

Most Efficient
#1110 / 1215


Fundamentals of Atara Biotherapeutics Inc

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

1.1. Profitability of Atara Biotherapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Atara Biotherapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -33,743.0% means that $-337.43 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Atara Biotherapeutics Inc:

  • The MRQ is -33,743.0%. The company is making a huge loss. -2
  • The TTM is -9,199.0%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-33,743.0%TTM-9,199.0%-24,544.0%
TTM-9,199.0%YOY-1,796.0%-7,403.0%
TTM-9,199.0%5Y-2,199.0%-7,000.0%
5Y-2,199.0%10Y-1,188.6%-1,010.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-33,743.0%-194.7%-33,548.3%
TTM-9,199.0%-273.6%-8,925.4%
YOY-1,796.0%-315.2%-1,480.8%
5Y-2,199.0%-539.0%-1,660.0%
10Y-1,188.6%-664.9%-523.7%
1.1.2. Return on Assets

Shows how efficient Atara Biotherapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
  • -19.8% Return on Assets means that Atara Biotherapeutics Inc generated $-0.20 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Atara Biotherapeutics Inc:

  • The MRQ is -19.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -15.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-19.8%TTM-15.1%-4.7%
TTM-15.1%YOY-18.0%+2.8%
TTM-15.1%5Y-17.5%+2.4%
5Y-17.5%10Y-13.5%-4.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-19.8%-12.4%-7.4%
TTM-15.1%-12.5%-2.6%
YOY-18.0%-10.9%-7.1%
5Y-17.5%-15.3%-2.2%
10Y-13.5%-17.6%+4.1%
1.1.3. Return on Equity

Shows how efficient Atara Biotherapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
  • -58.9% Return on Equity means Atara Biotherapeutics Inc generated $-0.59 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Atara Biotherapeutics Inc:

  • The MRQ is -58.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -34.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-58.9%TTM-34.0%-24.9%
TTM-34.0%YOY-26.4%-7.6%
TTM-34.0%5Y-24.7%-9.3%
5Y-24.7%10Y-16.9%-7.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-58.9%-15.2%-43.7%
TTM-34.0%-15.5%-18.5%
YOY-26.4%-13.1%-13.3%
5Y-24.7%-20.4%-4.3%
10Y-16.9%-20.9%+4.0%

1.2. Operating Efficiency of Atara Biotherapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Atara Biotherapeutics Inc is operating .

  • Measures how much profit Atara Biotherapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of -32,840.3% means the company generated $-328.40  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Atara Biotherapeutics Inc:

  • The MRQ is -32,840.3%. The company is operating very inefficient. -2
  • The TTM is -9,001.6%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-32,840.3%TTM-9,001.6%-23,838.6%
TTM-9,001.6%YOY-1,795.8%-7,205.9%
TTM-9,001.6%5Y-2,159.5%-6,842.2%
5Y-2,159.5%10Y-1,167.3%-992.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-32,840.3%-318.9%-32,521.4%
TTM-9,001.6%-267.4%-8,734.2%
YOY-1,795.8%-333.8%-1,462.0%
5Y-2,159.5%-517.0%-1,642.5%
10Y-1,167.3%-624.7%-542.6%
1.2.2. Operating Ratio

Measures how efficient Atara Biotherapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 342.81 means that the operating costs are $342.81 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Atara Biotherapeutics Inc:

  • The MRQ is 342.805. The company is inefficient in keeping operating costs low. -1
  • The TTM is 94.367. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ342.805TTM94.367+248.438
TTM94.367YOY18.976+75.391
TTM94.3675Y22.669+71.698
5Y22.66910Y12.253+10.415
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ342.8053.013+339.792
TTM94.3673.644+90.723
YOY18.9764.537+14.439
5Y22.6696.411+16.258
10Y12.2538.312+3.941

1.3. Liquidity of Atara Biotherapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Atara Biotherapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.74 means the company has $3.74 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Atara Biotherapeutics Inc:

  • The MRQ is 3.739. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.009. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.739TTM4.009-0.270
TTM4.009YOY4.464-0.455
TTM4.0095Y8.004-3.995
5Y8.00410Y17.113-9.109
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.7394.559-0.820
TTM4.0094.993-0.984
YOY4.4646.149-1.685
5Y8.0046.306+1.698
10Y17.1136.588+10.525
1.3.2. Quick Ratio

Measures if Atara Biotherapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 5.49 means the company can pay off $5.49 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Atara Biotherapeutics Inc:

  • The MRQ is 5.486. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.476. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.486TTM6.476-0.991
TTM6.476YOY7.171-0.694
TTM6.4765Y13.400-6.924
5Y13.40010Y28.385-14.985
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.4863.881+1.605
TTM6.4764.502+1.974
YOY7.1715.772+1.399
5Y13.4005.816+7.584
10Y28.3856.032+22.353

1.4. Solvency of Atara Biotherapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Atara Biotherapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Atara Biotherapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.66 means that Atara Biotherapeutics Inc assets are financed with 66.4% credit (debt) and the remaining percentage (100% - 66.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Atara Biotherapeutics Inc:

  • The MRQ is 0.664. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.500. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.664TTM0.500+0.163
TTM0.500YOY0.309+0.192
TTM0.5005Y0.239+0.261
5Y0.23910Y0.255-0.016
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6640.311+0.353
TTM0.5000.298+0.202
YOY0.3090.269+0.040
5Y0.2390.377-0.138
10Y0.2550.409-0.154
1.4.2. Debt to Equity Ratio

Measures if Atara Biotherapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 197.2% means that company has $1.97 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Atara Biotherapeutics Inc:

  • The MRQ is 1.972. The company is just able to pay all its debts with equity.
  • The TTM is 1.101. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.972TTM1.101+0.871
TTM1.101YOY0.457+0.644
TTM1.1015Y0.402+0.700
5Y0.40210Y0.240+0.161
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9720.363+1.609
TTM1.1010.362+0.739
YOY0.4570.277+0.180
5Y0.4020.424-0.022
10Y0.2400.463-0.223

2. Market Valuation of Atara Biotherapeutics Inc

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Atara Biotherapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -4.54 means the investor is paying $-4.54 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Atara Biotherapeutics Inc:

  • The EOD is -2.601. Company is losing money. -2
  • The MRQ is -4.538. Company is losing money. -2
  • The TTM is 5.802. Very good. +2
Trends
Current periodCompared to+/- 
EOD-2.601MRQ-4.538+1.937
MRQ-4.538TTM5.802-10.341
TTM5.802YOY-18.130+23.933
TTM5.8025Y-25.668+31.470
5Y-25.66810Y-64.109+38.441
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.601-6.504+3.903
MRQ-4.538-7.165+2.627
TTM5.802-8.417+14.219
YOY-18.130-19.810+1.680
5Y-25.668-18.328-7.340
10Y-64.109-18.049-46.060
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Atara Biotherapeutics Inc.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Atara Biotherapeutics Inc:

  • The MRQ is -4.053. Very Bad. -2
  • The TTM is 1.666. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ-4.053TTM1.666-5.719
TTM1.666YOY-18.789+20.455
TTM1.6665Y-30.373+32.039
5Y-30.37310Y-98.630+68.257
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4.053-4.287+0.234
TTM1.666-6.137+7.803
YOY-18.789-13.849-4.940
5Y-30.373-12.525-17.848
10Y-98.630-11.713-86.917

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Atara Biotherapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.67 means the investor is paying $2.67 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Atara Biotherapeutics Inc:

  • The EOD is 1.532. Good. +1
  • The MRQ is 2.672. Good. +1
  • The TTM is 2.999. Good. +1
Trends
Current periodCompared to+/- 
EOD1.532MRQ2.672-1.141
MRQ2.672TTM2.999-0.326
TTM2.999YOY4.769-1.770
TTM2.9995Y5.678-2.679
5Y5.67810Y7.378-1.700
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.5321.991-0.459
MRQ2.6722.024+0.648
TTM2.9992.335+0.664
YOY4.7693.965+0.804
5Y5.6783.738+1.940
10Y7.3784.004+3.374
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Atara Biotherapeutics Inc.

3.1. Institutions holding Atara Biotherapeutics Inc

Institutions are holding 103.982% of the shares of Atara Biotherapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2022-12-31BlackRock Inc9.52190.000991521492401582.6948
2022-12-31Wasatch Advisors Inc.8.730.185383910142546513.1298
2022-12-31Baupost Group LLC8.45180.4346812361600
2022-12-31State Street Corporation7.95880.00157649740-447613-5.5279
2022-12-31JPMorgan Chase & Co7.80240.00327499435-783953-9.4642
2022-12-31Vanguard Group Inc7.50230.000672110486045399.1507
2022-12-31Maverick Capital Ltd6.54510.48866291013-1564811-19.9191
2022-12-31Goldman Sachs Group Inc6.49580.00466243613148493331.2047
2022-12-31Redmile Group, LLC6.49490.8376624275600
2022-12-31D. E. Shaw & Co LP3.67470.0128353200081210029.8577
2022-12-31Morgan Stanley - Brokerage Accounts2.79840.0012689744-259172-8.7887
2022-09-30KPCB XV Associates LLC1.952519.7946187665000
2022-12-31Geode Capital Management, LLC1.91810.00091843618722944.0814
2022-12-31Citadel Advisors Llc1.45420.0011139776513661794325.2675
2022-12-31Ameriprise Financial Inc1.38730.0015133342046084452.8142
2022-12-31Nuveen Asset Management, LLC1.32630.00161274847752345143.9889
2022-12-31Citigroup Inc1.06680.00271025418-264213-20.4875
2022-12-31Antipodean Advisors LLC1.040410.9516100000000
2022-12-31Jacobs Levy Equity Management, Inc.1.00220.0214963272607947171.096
2022-12-31Dimensional Fund Advisors, Inc.0.9240.000988816527119743.9564
Total 88.047932.74784629283+3607425+4.3%

3.2. Funds holding Atara Biotherapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-03-31SPDR® S&P Biotech ETF5.41440.23445204123-60567-1.1504
2022-12-31Vanguard Instl Ttl Stck Mkt Idx Tr2.81970.0008271023636719615.6718
2023-03-31Vanguard Total Stock Mkt Idx Inv2.81970.0006271023600
2023-02-28JPMorgan Small Cap Growth A2.52620.2469242808100
2022-12-31Wasatch Small Cap Growth Investor2.46750.39332371687-70450-2.8848
2023-03-31JPM Global Healthcare C (acc) USD2.32970.1352223919600
2023-03-31iShares Russell 2000 ETF2.09580.01182014393-22806-1.1195
2022-12-31Wasatch Ultra Growth1.9580.47081881974-20204-1.0622
2022-12-31Wasatch Small Cap Value1.42880.3366137333400
2023-03-31Vanguard Extended Market Index Investor1.41280.00461357911270922.0357
2023-01-31Vanguard Explorer Inv1.15780.0277111288200
2023-03-31iShares Russell 2000 Value ETF0.93360.022789734632280.361
2023-03-31State St Russell Sm/Mid Cp® Indx NL Cl C0.88770.007885327700
2023-03-31JPM Thematics Genetic Thrps C2 Acc USD0.840.243980737400
2023-01-31Fidelity® Small Cap Index0.8040.0188772782165212.1846
2023-02-28CREF Stock R10.7540.00277246818904014.0079
2023-03-31Columbia Small Cap Value I0.74870.155719670230003.3014
2023-03-31Columbia Small Cap Value I A0.74870.155171967065000.9114
2023-03-31iShares Biotechnology ETF0.74220.0258713350-574-0.0804
2023-03-31Xtrackers S&P Global Infras Swap ETF 1C0.67610.63246498086498080
Total 33.56543.126932262011+1007784+3.1%

3.3. Insider Transactions

Insiders are holding 1.626% of the shares of Atara Biotherapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-03-02Jakob DupontSELL50743.63290794
2023-03-02Pascal TouchonSELL156793.63750728
2023-03-02Utpal KoppikarSELL68713.63181978
2023-03-02Amar MuruganSELL42213.63279334
2023-02-07Utpal KoppikarSELL24855.46188849
2022-11-16Amar MuruganSELL36124.49127586
2022-11-16Jakob DupontSELL43424.49154540
2022-11-16Pascal TouchonSELL155914.49441696
2022-11-16Utpal KoppikarSELL62554.49191334
2022-08-16Amar MuruganSELL34305.03131198
2022-08-16Utpal KoppikarSELL59405.04197589
2022-08-16Pascal TouchonSELL148065.04457287
2022-08-16Jakob DupontSELL41245.03158882
2022-06-27Pascal TouchonSELL142207.2472093
2022-05-17Amar MuruganSELL32235.32133735
2022-05-17Jakob DupontSELL38735.32163006
2022-05-17Pascal TouchonSELL139135.32486313
2022-05-17Utpal KoppikarSELL55825.32207592

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Atara Biotherapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.599-0.411-31%-0.479-20%-0.031-95%0.033-1907%
Book Value Growth--0.6770.838-19%0.883-23%1.033-35%1.288-47%
Book Value Per Share--1.2271.952-37%3.410-64%3.251-62%2.605-53%
Book Value Per Share Growth--0.6720.826-19%0.881-24%1.031-35%1.286-48%
Current Ratio--3.7394.009-7%4.464-16%8.004-53%17.113-78%
Debt To Asset Ratio--0.6640.500+33%0.309+115%0.239+178%0.255+160%
Debt To Equity Ratio--1.9721.101+79%0.457+331%0.402+391%0.240+721%
Dividend Per Share----0%-0%-0%-0%
Eps---0.723-0.559-23%-0.878+21%-0.716-1%-0.472-35%
Eps Growth--1.120-0.029+103%0.966+16%0.739+52%0.690+62%
Free Cash Flow Per Share---0.552-0.674+22%-0.597+8%-0.587+6%-0.381-31%
Free Cash Flow Per Share Growth--1.1330.776+46%-2.222+296%0.324+250%0.420+170%
Free Cash Flow To Equity Per Share---0.239-0.544+128%-0.329+38%-0.003-99%0.043-650%
Free Cash Flow To Equity Per Share Growth--1.626-0.187+111%1.340+21%1.515+7%2.015-19%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--13.619--------
Intrinsic Value_10Y_min---24.088--------
Intrinsic Value_1Y_max---1.801--------
Intrinsic Value_1Y_min---2.664--------
Intrinsic Value_3Y_max---2.998--------
Intrinsic Value_3Y_min---7.836--------
Intrinsic Value_5Y_max---1.287--------
Intrinsic Value_5Y_min---12.781--------
Net Profit Margin---337.430-91.990-73%-17.960-95%-21.990-93%-11.886-96%
Operating Margin---328.403-90.016-73%-17.958-95%-21.595-93%-11.673-96%
Operating Ratio--342.80594.367+263%18.976+1707%22.669+1412%12.253+2698%
Pb Ratio1.532-74%2.6722.999-11%4.769-44%5.678-53%7.378-64%
Pe Ratio-2.601+43%-4.5385.802-178%-18.130+299%-25.668+466%-64.109+1313%
Peg Ratio---4.0531.666-343%-18.789+364%-30.373+649%-98.630+2333%
Price Per Share1.880-74%3.2806.035-46%15.893-79%19.284-83%19.214-83%
Price To Total Gains Ratio-3.136+43%-5.4710.153-3679%-42.875+684%-10.569+93%-43.536+696%
Profit Growth--1.113-0.043+104%0.963+16%0.735+51%0.755+47%
Quick Ratio--5.4866.476-15%7.171-23%13.400-59%28.385-81%
Return On Assets---0.198-0.151-24%-0.180-9%-0.175-12%-0.135-32%
Return On Equity---0.589-0.340-42%-0.264-55%-0.247-58%-0.169-71%
Revenue Growth--0.0502.039-98%1.294-96%1.720-97%1.720-97%
Total Gains Per Share---0.599-0.411-31%-0.479-20%-0.031-95%0.033-1907%
Total Gains Per Share Growth--1.1450.346+231%0.625+83%1.478-23%2.082-45%
Usd Book Value--126640000.000198887000.000-36%330082500.000-62%316256450.000-60%252867459.459-50%
Usd Book Value Change Per Share---0.599-0.411-31%-0.479-20%-0.031-95%0.033-1907%
Usd Book Value Per Share--1.2271.952-37%3.410-64%3.251-62%2.605-53%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.723-0.559-23%-0.878+21%-0.716-1%-0.472-35%
Usd Free Cash Flow---56917000.000-68655750.000+21%-57775500.000+2%-57402650.000+1%-37174081.081-35%
Usd Free Cash Flow Per Share---0.552-0.674+22%-0.597+8%-0.587+6%-0.381-31%
Usd Free Cash Flow To Equity Per Share---0.239-0.544+128%-0.329+38%-0.003-99%0.043-650%
Usd Price Per Share1.880-74%3.2806.035-46%15.893-79%19.284-83%19.214-83%
Usd Profit---74572000.000-57046750.000-24%-85035250.000+14%-69831150.000-6%-45512054.054-39%
Usd Revenue--221000.00015893250.000-99%5085000.000-96%4195650.000-95%2267918.919-90%
Usd Total Gains Per Share---0.599-0.411-31%-0.479-20%-0.031-95%0.033-1907%
 EOD+3 -2MRQTTM+14 -25YOY+16 -235Y+10 -2910Y+6 -33

4.2. Fundamental Score

Let's check the fundamental score of Atara Biotherapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.601
Price to Book Ratio (EOD)Between0-11.532
Net Profit Margin (MRQ)Greater than0-337.430
Operating Margin (MRQ)Greater than0-328.403
Quick Ratio (MRQ)Greater than15.486
Current Ratio (MRQ)Greater than13.739
Debt to Asset Ratio (MRQ)Less than10.664
Debt to Equity Ratio (MRQ)Less than11.972
Return on Equity (MRQ)Greater than0.15-0.589
Return on Assets (MRQ)Greater than0.05-0.198
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Atara Biotherapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose1.640
Total0/1 (0.0%)



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets376,420
Total Liabilities249,780
Total Stockholder Equity126,640
 As reported
Total Liabilities 249,780
Total Stockholder Equity+ 126,640
Total Assets = 376,420

Assets

Total Assets376,420
Total Current Assets295,080
Long-term Assets295,080
Total Current Assets
Cash And Cash Equivalents 92,942
Short-term Investments 149,877
Net Receivables 40,221
Inventory 1,586
Other Current Assets 10,308
Total Current Assets  (as reported)295,080
Total Current Assets  (calculated)294,934
+/- 146
Long-term Assets
Property Plant Equipment 74,322
Long-term Assets Other 7,018
Long-term Assets  (as reported)81,340
Long-term Assets  (calculated)81,340
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities78,916
Long-term Liabilities170,864
Total Stockholder Equity126,640
Total Current Liabilities
Short-term Debt 13,640
Accounts payable 6,871
Other Current Liabilities 50,405
Total Current Liabilities  (as reported)78,916
Total Current Liabilities  (calculated)70,916
+/- 8,000
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt58,064
Long-term Liabilities Other 170,864
Long-term Liabilities  (as reported)170,864
Long-term Liabilities  (calculated)228,928
+/- 58,064
Total Stockholder Equity
Common Stock10
Retained Earnings -1,693,024
Accumulated Other Comprehensive Income -2,067
Capital Surplus 1,821,721
Total Stockholder Equity (as reported)126,640
Total Stockholder Equity (calculated)126,640
+/-0
Other
Capital Stock10
Cash and Short Term Investments 242,819
Common Stock Shares Outstanding 103,178
Common Stock Total Equity10
Current Deferred Revenue8,000
Liabilities and Stockholders Equity 376,420
Net Debt -34,878
Net Invested Capital 126,640
Net Tangible Assets 126,640
Net Working Capital 216,164
Short Long Term Debt Total 58,064



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-31
> Total Assets 
4,290
0
0
0
51,828
62,866
58,503
54,120
106,122
169,817
161,102
340,379
324,975
312,978
300,814
284,417
263,914
241,738
244,155
229,693
217,779
473,108
492,707
442,940
391,839
324,726
274,144
364,785
342,942
299,547
428,111
405,532
588,120
529,637
456,791
449,923
468,127
397,280
436,121
368,316
376,420
376,420368,316436,121397,280468,127449,923456,791529,637588,120405,532428,111299,547342,942364,785274,144324,726391,839442,940492,707473,108217,779229,693244,155241,738263,914284,417300,814312,978324,975340,379161,102169,817106,12254,12058,50362,86651,8280004,290
   > Total Current Assets 
0
0
0
0
51,808
62,291
57,085
52,022
106,026
169,691
160,634
340,235
324,597
311,741
298,883
282,230
260,553
235,318
222,492
206,217
172,190
413,614
425,070
372,976
321,489
250,830
201,139
293,418
272,992
229,217
358,987
339,432
523,273
464,307
392,325
369,497
384,621
314,389
346,984
283,046
295,080
295,080283,046346,984314,389384,621369,497392,325464,307523,273339,432358,987229,217272,992293,418201,139250,830321,489372,976425,070413,614172,190206,217222,492235,318260,553282,230298,883311,741324,597340,235160,634169,691106,02652,02257,08562,29151,8080000
       Cash And Cash Equivalents 
4,207
0
0
0
51,615
39,754
31,779
25,703
21,897
71,329
26,190
54,466
23,746
22,056
26,356
46,013
47,968
62,430
64,237
60,493
79,223
90,495
103,203
66,028
60,698
56,168
59,159
94,431
74,317
70,203
74,511
62,620
200,404
151,097
123,856
113,209
106,084
101,669
70,688
65,114
92,942
92,94265,11470,688101,669106,084113,209123,856151,097200,40462,62074,51170,20374,31794,43159,15956,16860,69866,028103,20390,49579,22360,49364,23762,43047,96846,01326,35622,05623,74654,46626,19071,32921,89725,70331,77939,75451,6150004,207
       Short-term Investments 
0
0
0
0
0
22,277
24,719
25,996
82,219
95,367
128,841
279,799
296,736
284,347
268,201
232,134
207,714
168,216
152,659
139,728
86,873
316,826
313,812
298,515
248,933
181,377
130,976
188,491
184,792
144,428
273,201
264,565
300,255
284,064
249,524
244,036
264,984
200,142
260,623
200,290
149,877
149,877200,290260,623200,142264,984244,036249,524284,064300,255264,565273,201144,428184,792188,491130,976181,377248,933298,515313,812316,82686,873139,728152,659168,216207,714232,134268,201284,347296,736279,799128,84195,36782,21925,99624,71922,27700000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
800
800
1,250
9,610
700
400
986
668
637
249
40,221
40,2212496376689864007009,6101,250800800000000000000000000000000000000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,586
1,5860000000000000000000000000000000000000000
   > Long-term Assets 
0
0
0
0
20
575
1,418
2,098
96
126
468
144
378
1,237
1,931
2,187
3,361
6,420
21,663
23,476
45,589
59,494
67,637
69,964
70,350
73,896
73,005
71,367
69,950
70,330
69,124
66,100
64,847
65,330
64,466
80,426
83,506
82,891
89,137
85,270
81,340
81,34085,27089,13782,89183,50680,42664,46665,33064,84766,10069,12470,33069,95071,36773,00573,89670,35069,96467,63759,49445,58923,47621,6636,4203,3612,1871,9311,237378144468126962,0981,418575200000
       Property Plant Equipment 
9
0
0
0
8
8
11
14
48
47
42
46
270
1,148
1,830
2,085
3,259
4,400
20,287
22,176
44,129
58,194
66,075
68,279
68,576
72,160
71,486
69,901
68,183
68,133
66,908
64,023
62,820
63,401
62,577
78,556
79,939
28,042
81,910
78,104
74,322
74,32278,10481,91028,04279,93978,55662,57763,40162,82064,02366,90868,13368,18369,90171,48672,16068,57668,27966,07558,19444,12922,17620,2874,4003,2592,0851,8301,148270464247481411880009
       Long-term Assets Other 
0
0
0
0
12
567
1,407
2,084
48
79
426
98
108
89
101
102
102
2,020
1,376
1,300
1,460
1,300
1,562
1,685
1,774
1,736
1,519
1,466
1,767
2,197
2,216
2,077
2,027
1,929
1,889
1,870
3,567
54,849
7,227
7,166
7,018
7,0187,1667,22754,8493,5671,8701,8891,9292,0272,0772,2162,1971,7671,4661,5191,7361,7741,6851,5621,3001,4601,3001,3762,020102102101891089842679482,0841,407567120000
> Total Liabilities 
1,306
0
0
0
62,845
77,570
2,280
77,149
2,940
3,723
11,847
6,631
9,875
9,144
10,569
14,215
10,178
8,604
23,011
23,737
39,915
33,924
40,208
39,886
52,982
40,792
41,865
46,343
52,161
46,725
46,986
51,597
125,781
130,600
125,253
139,782
188,513
172,964
178,642
181,203
249,780
249,780181,203178,642172,964188,513139,782125,253130,600125,78151,59746,98646,72552,16146,34341,86540,79252,98239,88640,20833,92439,91523,73723,0118,60410,17814,21510,5699,1449,8756,63111,8473,7232,94077,1492,28077,57062,8450001,306
   > Total Current Liabilities 
1,302
0
0
0
1,524
2,788
2,101
2,412
2,724
3,514
11,644
6,450
9,709
8,860
10,006
13,688
9,675
7,805
11,481
16,516
27,646
21,049
27,234
27,000
39,979
25,175
25,803
30,706
36,743
31,520
31,684
36,055
82,901
84,194
88,830
86,150
105,786
101,562
65,688
72,244
78,916
78,91672,24465,688101,562105,78686,15088,83084,19482,90136,05531,68431,52036,74330,70625,80325,17539,97927,00027,23421,04927,64616,51611,4817,8059,67513,68810,0068,8609,7096,45011,6443,5142,7242,4122,1012,7881,5240001,302
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
500
10,300
10,300
0
0
643
0
0
1,581
0
0
0
1,985
0
0
0
2,753
0
0
0
13,640
13,6400002,7530001,9850001,581006430010,30010,30050000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
500
10,300
10,300
0
0
643
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000006430010,30010,30050000000000000000000000
       Accounts payable 
121
0
0
0
606
1,402
577
569
440
794
1,703
1,853
1,445
1,896
3,235
4,463
2,778
2,204
5,243
5,539
14,711
6,098
6,545
6,193
3,719
6,168
6,420
5,155
7,963
8,079
5,106
5,190
7,118
17,355
12,301
16,543
17,368
11,945
12,799
11,296
6,871
6,87111,29612,79911,94517,36816,54312,30117,3557,1185,1905,1068,0797,9635,1556,4206,1683,7196,1936,5456,09814,7115,5395,2432,2042,7784,4633,2351,8961,4451,8531,7037944405695771,402606000121
       Other Current Liabilities 
1,174
0
0
0
918
1,386
1,524
1,843
2,284
2,720
9,941
4,597
8,264
6,964
6,771
9,225
6,897
5,601
6,238
10,977
12,935
14,951
20,689
20,807
36,260
19,007
19,383
25,551
27,199
23,441
26,578
30,865
40,343
31,342
35,561
38,381
44,905
38,674
51,218
58,286
50,405
50,40558,28651,21838,67444,90538,38135,56131,34240,34330,86526,57823,44127,19925,55119,38319,00736,26020,80720,68914,95112,93510,9776,2385,6016,8979,2256,7716,9648,2644,5979,9412,7202,2841,8431,5241,3869180001,174
   > Long-term Liabilities 
0
0
0
0
61,321
74,782
179
74,737
216
209
203
181
166
284
563
527
503
799
11,530
7,221
12,269
12,875
12,974
12,886
13,003
15,617
16,062
15,637
15,418
15,205
15,302
15,542
42,880
46,406
36,423
53,632
82,727
71,402
112,954
108,959
170,864
170,864108,959112,95471,40282,72753,63236,42346,40642,88015,54215,30215,20515,41815,63716,06215,61713,00312,88612,97412,87512,2697,22111,53079950352756328416618120320921674,73717974,78261,3210000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
196
141
85
244
0
0
0
0
0
0
0
0
0
0
0
0
000000000000244851411960000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-500
-10,300
-10,300
0
0
13,794
14,919
14,532
14,136
13,809
13,420
13,129
13,041
12,569
12,182
24,574
22,765
17,453
63,999
61,072
58,064
58,06461,07263,99917,45322,76524,57412,18212,56913,04113,12913,42013,80914,13614,53214,91913,79400-10,300-10,300-50000000000000000000000
       Warrants
0
0
0
0
0
0
0
149,144
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000149,1440000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
165
216
209
203
181
0
0
0
0
0
0
0
0
0
0
0
0
0
15,617
16,062
15,637
15,418
15,205
15,302
15,542
42,880
46,406
1,771
53,632
1,501
71,402
5,626
108,959
170,864
170,864108,9595,62671,4021,50153,6321,77146,40642,88015,54215,30215,20515,41815,63716,06215,61700000000000001812032092161650000000
> Total Stockholder Equity
2,984
0
0
0
-11,017
-14,704
56,223
-23,029
103,182
166,094
149,255
333,748
315,100
303,834
290,245
270,202
253,736
233,134
221,144
205,956
177,864
439,184
452,499
403,054
338,857
283,934
232,279
318,442
290,781
252,822
381,125
353,935
462,339
399,037
331,538
310,141
279,614
224,316
257,479
187,113
126,640
126,640187,113257,479224,316279,614310,141331,538399,037462,339353,935381,125252,822290,781318,442232,279283,934338,857403,054452,499439,184177,864205,956221,144233,134253,736270,202290,245303,834315,100333,748149,255166,094103,182-23,02956,223-14,704-11,0170002,984
   Common Stock
1
0
0
0
1
0
1
0
2
2
2
3
3
3
3
3
3
3
3
3
3
4
5
5
5
5
5
5
6
6
7
8
8
8
8
9
9
9
9
9
10
109999988887665555554333333333322201010001
   Retained Earnings Total Equity-1,693,024-1,618,452-1,534,361-1,552,827-1,464,722-1,371,373-1,286,709-1,202,916-1,124,581-1,043,274-968,926-891,470-817,961-739,465-667,570-593,242-527,349-447,337-388,976-338,093-296,650-261,337-230,241-202,813-177,159-158,924-133,551-114,671-98,110-76,862-64,994-50,049-40,889-30,3620000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-3,823
-11
0
-11
-100
-18
-66
51
-518
51
193
35
-183
-152
-114
-88
-151
-524
-505
-449
-340
38
173
233
220
204
810
527
296
161
62
24
-368
-1,892
-2,618
-2,959
-2,067
-2,067-2,959-2,618-1,892-368246216129652781020422023317338-340-449-505-524-151-88-114-152-1833519351-51851-66-18-100-110-11-3,8230000
   Capital Surplus 
0
0
0
0
0
0
0
7,344
144,169
216,159
214,313
410,556
413,725
418,451
423,600
429,088
431,075
436,096
451,496
467,378
474,662
777,797
841,975
850,835
866,541
877,133
899,671
1,057,669
1,108,516
1,144,082
1,349,234
1,396,674
1,586,616
1,601,784
1,618,177
1,681,481
1,744,695
1,779,026
1,794,449
1,808,515
1,821,721
1,821,7211,808,5151,794,4491,779,0261,744,6951,681,4811,618,1771,601,7841,586,6161,396,6741,349,2341,144,0821,108,5161,057,669899,671877,133866,541850,835841,975777,797474,662467,378451,496436,096431,075429,088423,600418,451413,725410,556214,313216,159144,1697,3440000000
   Treasury Stock00000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
1,865
5,239
84,477
7,344
144,169
216,159
214,313
410,556
413,725
418,451
423,600
429,088
431,075
436,096
451,496
467,378
474,662
777,797
841,975
850,835
866,541
877,133
899,671
1,057,669
1,108,516
1,144,082
1,349,234
1,396,674
1,586,616
1,601,784
1,618,177
1,681,481
1,744,695
1,779,026
1,794,449
1,808,515
1,821,721
1,821,7211,808,5151,794,4491,779,0261,744,6951,681,4811,618,1771,601,7841,586,6161,396,6741,349,2341,144,0821,108,5161,057,669899,671877,133866,541850,835841,975777,797474,662467,378451,496436,096431,075429,088423,600418,451413,725410,556214,313216,159144,1697,34484,4775,2391,8650000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue63,573
Cost of Revenue--
Gross Profit63,57363,573
 
Operating Income (+$)
Gross Profit63,573
Operating Expense-344,086
Operating Income-280,513-280,513
 
Operating Expense (+$)
Research Development272,533
Selling General Administrative71,553
Selling And Marketing Expenses-
Operating Expense344,086344,086
 
Net Interest Income (+$)
Interest Income1,986
Interest Expense-1,986
Other Finance Cost-1,986
Net Interest Income1,986
 
Pretax Income (+$)
Operating Income-280,513
Net Interest Income1,986
Other Non-Operating Income Expenses52,223
Income Before Tax (EBT)-228,290-332,736
EBIT - interestExpense = -282,499
-228,290
-226,316
Interest Expense1,986
Earnings Before Interest and Taxes (EBIT)-280,513-226,304
Earnings Before Interest and Taxes (EBITDA)-330,750
 
After tax Income (+$)
Income Before Tax-228,290
Tax Provision-12
Net Income From Continuing Ops-228,302-228,302
Net Income-228,302
Net Income Applicable To Common Shares-228,302
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses344,086
Total Other Income/Expenses Net52,223-54,209
 

Technicals of Atara Biotherapeutics Inc

1. Trend Indicators

1.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Atara Biotherapeutics Inc Daily Moving Averages ChartAtara Biotherapeutics Inc Daily Moving Averages Chart
1.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Let's take a look of the Moving Average Convergence/Divergence (MACD) of Atara Biotherapeutics Inc:

    Atara Biotherapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAtara Biotherapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
    1.3 Directional Movement Index (DMI)

    The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index).

    The ADX helps you determine the strength of a trend. Let's take a look of the ADX of Atara Biotherapeutics Inc:

    • The ADX is .